Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Mutations in the T-cell receptor signalling pathway are linked to adult T-cell leukaemia/lymphoma (ATLL).
• Protein kinase C beta (PKCβ) is a frequent mutation target in ATLL.
• The D427N mutation is the most common alteration observed in PKCβ.

Purpose of the Study:

• To characterize the D427N mutation in PKCβ.
• To determine if the mutation results in gain-of-function, loss-of-function, or neomorphic changes.
• To assess the mutation's impact in vitro, in cells, biochemically, and structurally.

Main Methods:

• Biochemical assays to assess protein kinase activity and substrate specificity.
• Cellular assays to evaluate the mutation's effects in a cellular context.
• Structural biology techniques to determine the D427N mutant-ruboxistaurin structure.
• In vivo studies using a constitutive knock-in mouse model.

Main Results:

• The D427N mutation represents a gain-of-function, activating mutation.
• The mutation alters the substrate specificity of PKCβ.
• The activated allele in a knock-in mouse model induced splenomegaly and extramedullary haematopoiesis.
• The D427N mutant protein shows reduced sensitivity to existing PKCβ inhibitors.

Conclusions:

• The D427N mutation in PKCβ is a driver of ATLL.
• Targeting this mutated PKCβ requires the development of novel therapeutics.
• The determined structure of the D427N mutant-ruboxistaurin can guide the design of new drugs.